Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868894 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
A Phase 1 study, sponsored by Santen.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00868894: Completed Phase 1 study, sponsored by Santen.
NCT00868894 is a Phase 1 study that has completed, run by Santen. The registered enrollment target is 49 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00868894, a Phase 1 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Placebo
- DRUG DE-104 medium concentration
- DRUG DE-104 high concentration
- DRUG 0.005% latanoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
What the finished NCT00868894 record still lists
NCT00868894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00868894 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00868894 about?
NCT00868894 is a clinical study titled "Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension". To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00868894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2009-03. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00868894?
The interventions under investigation include: Placebo (DRUG), DE-104 medium concentration (DRUG), DE-104 high concentration (DRUG), 0.005% latanoprost (DRUG).
Who is sponsoring clinical trial NCT00868894?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00868894's enrollment target sits among peer trials
49 1017th of 2000 higher than 976 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia